<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aarti Sharma</style></author><author><style face="normal" font="default" size="100%">Himanshu Gupta</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">PHARMACOVIGILENCE AND CLINICAL TRIALS</style></title><secondary-title><style face="normal" font="default" size="100%">The Pharma Review</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style  face="normal" font="default" size="100%">pharmacovigilence</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">05/2009</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">KPpub</style></publisher><volume><style face="normal" font="default" size="100%">7</style></volume><abstract><style face="normal" font="default" size="100%">Clinical and preclinical studies cannot guarantee absolute safety of a drug. Therefore pharmacovigilance has been introduced to identify and respond to drug safety issue. It is related to the surveillance of drugs once they are released for use in the community (post marketing surveillance) and relies on voluntary reporting, prescription monitoring, medical records and statistical studies in the population. It is important that adequate Pharmacovigilance standards are introduced to monitor adverse reactions of products, before its launches in country like India. In this article we have tried to give an insight view on different aspect of pharmacovigilance.</style></abstract><issue><style face="normal" font="default" size="100%">39</style></issue></record></records></xml>